Tetra Bio-Pharma Confirms it is on Track to Receive Government Funding - Press Release
Tetra Provides Update on ARDS-003 Tetra Eyes Global Sepsis Market OTTAWA, ON / ACCESSWIRE / December 21, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced that it expects government funding to help accelerate its sepsis and acute respiratory distress syndrome (ARDS) drug development. As the first Endocannabinoid System (ECS) biotechnology company tackling sepsis, a life-threatening condition associated with COVID-19 and other inflammatory conditions including pneumonia and tumors, we...
Source: digitaljournal.com